ProQR Therapeutics (NASDAQ:PRQR – Get Rating)’s stock price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.76 and traded as high as $0.82. ProQR Therapeutics shares last traded at $0.81, with a volume of 184,272 shares traded.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on PRQR. JMP Securities decreased their price target on ProQR Therapeutics from $8.00 to $5.00 and set a “market outperform” rating for the company in a research note on Thursday, April 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of ProQR Therapeutics in a research note on Monday, May 9th. Chardan Capital decreased their price target on ProQR Therapeutics from $8.00 to $2.50 and set a “buy” rating for the company in a research note on Thursday, April 14th. StockNews.com raised ProQR Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 9th. Finally, HC Wainwright cut their price objective on ProQR Therapeutics from $4.00 to $2.00 in a report on Monday, May 9th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $7.43.
ProQR Therapeutics Stock Performance
The firm has a market capitalization of $57.42 million, a PE ratio of -0.75 and a beta of 0.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.27 and a quick ratio of 7.27. The firm has a fifty day moving average price of $0.76 and a 200 day moving average price of $1.69.
Institutional Investors Weigh In On ProQR Therapeutics
Several hedge funds have recently modified their holdings of PRQR. Privium Fund Management UK Ltd purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $38,935,000. M28 Capital Management LP purchased a new stake in ProQR Therapeutics in the 1st quarter worth about $907,000. Renaissance Technologies LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth about $547,000. Goldman Sachs Group Inc. lifted its stake in ProQR Therapeutics by 14.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company’s stock worth $31,346,000 after acquiring an additional 481,325 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its stake in ProQR Therapeutics by 10.0% in the 1st quarter. Privium Fund Management B.V. now owns 5,244,446 shares of the biopharmaceutical company’s stock worth $4,747,000 after acquiring an additional 478,787 shares in the last quarter.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- 3 Large Caps With Bullish Chart Patterns
- Medtronic Stock Keeps Ticking Forward
- The Bull and Bear Case for Investing in AMD
- Occidental Petroleum Leads Exxon Mobil, Chevron Ahead Of Next Week’s Earnings
- Simpson Manufacturing Quietly Builds Foundations For Growth
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.